MTHFR and non-small cell lung carcinoma: Smit et al reported that patients with an MTHFR TT homozygous mutation had increased PFS compared with wild-type or heterozygous NSCLC patients treated with pemetrexed [7.9 months, (95% CI, 3.9–16 months) vs. 2.9 months, (95% CI, 2.8–3.4 months); P=0.03] in (16).